Fig. 4
From: Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway
Genetic increase of TSPO in astrocytes alleviated neuropathic pain by reducing pyroptosis. A Representative immunofluorescence images showing TSPO/NeuN, TSPO/GFAP, and TSPO/Iba1 co-staining, Scale bar = 50 μm. B Schematic diagram of the experimental flow. C Representative immunofluorescence images showing AS-TSPO colocalized with GFAP + astrocytes, scale bar = 50 μm. D Western blot shows the expression levels of TSPO in AS-TSPO or AS-TSPO-Ctrl treated conditions. E Behavioral changes following TSPO activation by AS-TSPO were assessed using von Frey tests at multiple time points (days 0, 3, 7, 14, and 21), n = 10 per group. F Representative immunofluorescence images showing c-Fos and NeuN co-staining after AS-TSPO treatment, Scale bar = 50 μm. G, H ELISA results showing the levels of IL-1β and IL-18 after AS-TSPO treatment, n = 6 per group. I Western blot showing the expression levels of TSPO, NLRP3, Caspase-1 and GSDMD-N after AS-TSPO treatment. Data are represented as mean ± SEM, ***p < 0.001